A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients

Synne Jenum; Kristian Tonby; Corina S. Rueegg; Morten Rühwald; Max P. Kristiansen; Peter Bang; Inge Christoffer Olsen; Kjersti Sellæg; Kjerstin Røstad; Tehmina Mustafa; Kjetil Taskén; Dag Kvale; Rasmus Mortensen; Anne Ma Dyrhol-Riise

doi:10.1038/s41467-021-27029-6

Nature Communications (Nov 2021)

A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients

Synne Jenum,
Kristian Tonby,
Corina S. Rueegg,
Morten Rühwald,
Max P. Kristiansen,
Peter Bang,
Inge Christoffer Olsen,
Kjersti Sellæg,
Kjerstin Røstad,
Tehmina Mustafa,
Kjetil Taskén,
Dag Kvale,
Rasmus Mortensen,
Anne Ma Dyrhol-Riise

Affiliations

Synne Jenum: Department of Infectious diseases, Oslo University Hospital
Kristian Tonby: Department of Infectious diseases, Oslo University Hospital
Corina S. Rueegg: Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital
Morten Rühwald: Center for Vaccine Research, Department of Infectious Disease Immunology, Statens Serum Institut Artillerivej 5
Max P. Kristiansen: Center for Vaccine Research, Vaccine Development, Statens Serum Institut
Peter Bang: Center for Vaccine Research, Vaccine Development, Statens Serum Institut
Inge Christoffer Olsen: Department of Research Support for Clinical Trials,, Oslo University Hospital
Kjersti Sellæg: Department of Infectious diseases, Oslo University Hospital
Kjerstin Røstad: Department of Infectious diseases, Oslo University Hospital
Tehmina Mustafa: Centre for International Health, Department of Global Public Health and Primary Care, University of Bergen
Kjetil Taskén: Institute of Clinical Medicine, University of Oslo
Dag Kvale: Department of Infectious diseases, Oslo University Hospital
Rasmus Mortensen: Center for Vaccine Research, Department of Infectious Disease Immunology, Statens Serum Institut Artillerivej 5
Anne Ma Dyrhol-Riise: Department of Infectious diseases, Oslo University Hospital

DOI: https://doi.org/10.1038/s41467-021-27029-6
Journal volume & issue: Vol. 12, no. 1
pp. 1 – 13

Abstract

Read online

Modulating the host immune response during tuberculosis is an emerging and critical advance in the therapeutic approach. Here the authors present data from a first-in-human phase I/II randomised trial on the safety and immunogenicity of adjuvant therapy of the H56:IC31 vaccine and cyclooxygenase-2 inhibitors in patients with tuberculosis.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal